Natco Pharma Ltd

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 June to 19 June 2025. At the conclusion of inspection, the USFDA has issued a Form 483 with seven observations. Natco Pharma expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to current Good Manufacturing Practices (cGMP) and the consistent supply of high-quality pharmaceutical products to global markets. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company's consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The counter shed 0.98% to Rs 872.75 on the BSE. Powered by Capital Market - Live

On conclusion of the inspection, the company received one observation in the Form-483. The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company's consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday. Powered by Capital Market - Live

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active Pharmaceutical Ingredients (API) Unit The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 9th June - 13th June 2025. On conclusion of the inspection, the Company received 1 (One) observation in the Form-483. The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively. Powered by Capital Market - Live

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908.15, up 3.01% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Natco Pharma Ltd has risen around 8.92% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has risen around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 13.07 lakh shares today, compared to the daily average of 7.32 lakh shares in last one month.The PE of the stock is 8.53 based on TTM earnings ending March 25.Powered by Capital Market - Live

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st March 2025. EBITDA stood at Rs 614.4 crore, registering the growth of 13.93% compared with Rs 539.3 crore posted in corresponding quarter last year. EBITDA margin reduced to 47.7% in Q4 FY25 as against 48.6% in Q4 FY24. During the quarter, the company recorded an impairment charge of Rs 50 crore in the crop health science business related to property, plant and machinery and a chargeback adjustment of approximately Rs 25 crore in its US subsidiary. On full year basis, the company's consolidated net profit jumped 35.8% to Rs 1,885.40 crore on 10.8% increase in revenue from operations to Rs 4,429.50 crore in FY25 over FY24. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.Powered by Capital Market - Live

Net profit of Natco Pharma rose 5.25% to Rs 406.60 crore in the quarter ended March 2025 as against Rs 386.30 crore during the previous quarter ended March 2024. Sales rose 14.29% to Rs 1221.00 crore in the quarter ended March 2025 as against Rs 1068.30 crore during the previous quarter ended March 2024. For the full year,net profit rose 35.81% to Rs 1885.40 crore in the year ended March 2025 as against Rs 1388.30 crore during the previous year ended March 2024. Sales rose 10.77% to Rs 4429.50 crore in the year ended March 2025 as against Rs 3998.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1221.001068.30 14 4429.503998.80 11 OPM %44.8946.55 -49.5843.80 - PBDT604.20533.10 13 2526.601860.30 36 PBT505.90477.60 6 2291.401673.50 37 NP406.60386.30 5 1885.401388.30 36 Powered by Capital Market - Live

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify that the Ld. Single Judge of Delhi High Court had through order dated 24 March 2025 denied Roche's plea for an injunction against the Company for the drug. However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the Company does not wish to comment on the status of the proceedings. However, it has been the stand of the Company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of the Delhi High Court which is expected shortly. Subject to the foregoing, the Company has decided to price the product at Rs 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer discount to certain deserving patients through its patient access programme.Powered by Capital Market - Live

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 823.5, up 0.06% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Natco Pharma Ltd has dropped around 35.76% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 3.53 lakh shares today, compared to the daily average of 19.39 lakh shares in last one month.The PE of the stock is 8.31 based on TTM earnings ending December 24.Powered by Capital Market - Live

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837, up 1.69% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 22571.15. The Sensex is at 74623.15, up 0.23%. Natco Pharma Ltd has dropped around 28.81% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has dropped around 4.72% in last one month and is currently quoting at 20389.7, down 0.5% on the day. The volume in the stock stood at 6.37 lakh shares today, compared to the daily average of 15.09 lakh shares in last one month.The PE of the stock is 8.31 based on TTM earnings ending December 24.Powered by Capital Market - Live